SCOTT SCHNEIDERMAN: Open Payments
NPI 1073693289 · MONTEREY, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,173 in 41 payments from 20 companies in 2025. Trend: 2023 $1,744 · 2024 $1,215 · 2025 $1,173
Food & beverage: $1,173
| Company | Payments | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $232 |
| Bard Peripheral Vascular, Inc. | 1 | $165 |
| ABBVIE INC. | 13 | $144 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $76 |
| Novartis Pharmaceuticals Corporation | 2 | $61 |
| Lundbeck LLC | 2 | $60 |
| Collegium Pharmaceutical, Inc. | 3 | $58 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $47 |
| Edwards Lifesciences Corporation | 1 | $35 |
| Novo Nordisk Inc | 1 | $34 |
Products named: JARDIANCE, Venclose Maven Catheter, REXULTI, VRAYLAR, CAPLYTA, LEQVIO, Belbuca, UBRELVY.
Industry payments across CA — which companies pay providers there.
